KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma

Shuang-Ni Yu; Yi-Hui Ma; Wu-Gan Zhao; Xiang-Lan Jin; Hai-Yan Yang; Ping-Ping Liu; Jie Chen

doi:10.1016/j.cdtm.2016.11.012

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma

Chronic Dis Transl Med. 2016 Dec 22;2(4):215-222. doi: 10.1016/j.cdtm.2016.11.012. eCollection 2016 Dec.

Authors

Shuang-Ni Yu¹, Yi-Hui Ma^{1

2}, Wu-Gan Zhao^{1

2}, Xiang-Lan Jin^{1

3}, Hai-Yan Yang^{1

4}, Ping-Ping Liu^{1

5}, Jie Chen¹

Affiliations

¹ Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tsinghua University, Beijing 100730, China.
² Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
³ Department of Pathology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
⁴ Department of Pathology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
⁵ Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a poor overall prognosis. However, curative resection during the early stages of the disease can greatly improve survival rates, highlighting the importance of early screening and detection. Studies of noncoding RNAs, primarily microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), provide important insights into strategies for the early detection of KRAS-driven PDAC. Here, we summarize our studies and review current reports on research investigating KRAS-related miRNAs and lncRNAs, emphasizing their aberrant expression, mechanisms, carcinogenic effects, and prognostic and predictive capacities in PDAC.

Keywords: KRAS; Long noncoding RNAs; Noncoding RNAs; Pancreatic ductal adenocarcinoma; microRNAs.

Publication types

Review